IL2 and cancer: In DC, BH treatments downregulated genes (Figure A6D) that were associated with the α/β T cell activation, IL-2 production, T cell costimulation differentiation activation and signalling, and a small number of genes associated with the TAP and class I MHC complexes, and the NK mediated anti-cancer immune response (Figure 7D).